Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a
Identifieur interne : 004D47 ( PascalFrancis/Checkpoint ); précédent : 004D46; suivant : 004D48Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a
Auteurs : Frederik Barkhof [Pays-Bas] ; Mara Rocca [Italie] ; Gordon Francis [États-Unis] ; Jan-Hein T. M. Van Waesberghe [Pays-Bas] ; Bernard M. J. Uitdehaag [Pays-Bas] ; Otto R. Hommes [Pays-Bas] ; Hans-Peter Hartung [Autriche] ; Luca Durelli [Italie] ; Gilles Edan [France] ; Oscar Fernandez [Espagne] ; Pierette Seeldrayers [Belgique] ; Per S Rensen [Danemark] ; Simon Margrie [Australie] ; Marco Rovaris [Italie] ; Giancarlo Comi [Italie] ; Massimo Filippi [Italie]Source :
- Annals of neurology [ 0364-5134 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
In the recently proposed diagnostic criteria for multiple sclerosis (MS) by McDonald, the modified magnetic resonance imaging (MRI) Barkhof criteria have been incorporated. We examined the validity of this implementation in the Early Treatment of MS study, a randomized, double-blind, placebo-controlled study of 22μg interferon β1a given subcutaneously once weekly in 309 patients with a first episode consistent with demyelinating disease (and abnormal MRI). Conversion to clinically definite MS (CDMS) within 2 years of follow-up, as evidenced by a new clinical episode, occurred in 41% of patients (independent of treatment) with gadolinium enhancement or nine or more T2 lesions versus 11% of those without either finding (p = 0.017); similarly, proportions converting were 44% versus 31% for infratentorial lesions (p = 0.026), 40% versus 35% for juxtacortical lesions (p = 0.413), and 41% versus 17% for three or more periventricular lesions (p = 0.034). The rate of conversion to CDMS based on the number of modified Barkhof criteria was 22% for two or fewer positive criteria, increasing to 47% with four positive criteria. For a cutoff of three positive criteria, the hazard ratio for time to CDMS was 2.3 (95% confidence interval, 1.17-4.55; p = 0.016). Treatment effect seemed more evident as the number of positive criteria increased, and the number of patients needed to avoid one patient converting to CDMS decreased from 50 in patients with one or two positive criteria to 5.6 in patients with four positive criteria. However, the study was not powered to detect statistically significant treatment by variable interaction, and this remains an important issue for further study.
Affiliations:
- Australie, Autriche, Belgique, Danemark, Espagne, France, Italie, Pays-Bas, États-Unis
- Gueldre, Hollande-Septentrionale, Hovedstaden, Lombardie, Nouvelle-Galles du Sud, Piémont, Région Bretagne, Région de Bruxelles-Capitale
- Amsterdam, Bruxelles, Copenhague, Milan, Nimègue, Rennes, Sydney, Turin
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:03-0451872Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a</title><author><name sortKey="Barkhof, Frederik" sort="Barkhof, Frederik" uniqKey="Barkhof F" first="Frederik" last="Barkhof">Frederik Barkhof</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MS-MRI Centre and Department of Radiology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Rocca, Mara" sort="Rocca, Mara" uniqKey="Rocca M" first="Mara" last="Rocca">Mara Rocca</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neuroimaging Research Unit, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>2 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Francis, Gordon" sort="Francis, Gordon" uniqKey="Francis G" first="Gordon" last="Francis">Gordon Francis</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Serono Laboratories</s1><s2>Rockland, MA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Serono Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Van Waesberghe, Jan Hein T M" sort="Van Waesberghe, Jan Hein T M" uniqKey="Van Waesberghe J" first="Jan-Hein T. M." last="Van Waesberghe">Jan-Hein T. M. Van Waesberghe</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MS-MRI Centre and Department of Radiology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Uitdehaag, Bernard M J" sort="Uitdehaag, Bernard M J" uniqKey="Uitdehaag B" first="Bernard M. J." last="Uitdehaag">Bernard M. J. Uitdehaag</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>MS-MRI Centre and Department of Neurology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Hommes, Otto R" sort="Hommes, Otto R" uniqKey="Hommes O" first="Otto R." last="Hommes">Otto R. Hommes</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>European Charcot Foundation</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Hartung, Hans Peter" sort="Hartung, Hans Peter" uniqKey="Hartung H" first="Hans-Peter" last="Hartung">Hans-Peter Hartung</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Karl-Franzens Universitat</s1><s2>Graz</s2><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Graz</wicri:noRegion></affiliation></author><author><name sortKey="Durelli, Luca" sort="Durelli, Luca" uniqKey="Durelli L" first="Luca" last="Durelli">Luca Durelli</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Neurology, University of Turin</s1><s2>Turin</s2><s3>ITA</s3><sZ>8 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Edan, Gilles" sort="Edan, Gilles" uniqKey="Edan G" first="Gilles" last="Edan">Gilles Edan</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Clinique Neurologique, Université de Rennes</s1><s2>Rennes</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Fernandez, Oscar" sort="Fernandez, Oscar" uniqKey="Fernandez O" first="Oscar" last="Fernandez">Oscar Fernandez</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Servicio de Neurología, Hospital Carlos Haya</s1><s2>Málaga</s2><s3>ESP</s3><sZ>10 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>Málaga</wicri:noRegion></affiliation></author><author><name sortKey="Seeldrayers, Pierette" sort="Seeldrayers, Pierette" uniqKey="Seeldrayers P" first="Pierette" last="Seeldrayers">Pierette Seeldrayers</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Neurology, C.H.U. de Charleroi, and Hôpital Erasme</s1><s2>Brussels</s2><s3>BEL</s3><sZ>11 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="S Rensen, Per" sort="S Rensen, Per" uniqKey="S Rensen P" first="Per" last="S Rensen">Per S Rensen</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Neurology, Rigshospitalet</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>12 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Margrie, Simon" sort="Margrie, Simon" uniqKey="Margrie S" first="Simon" last="Margrie">Simon Margrie</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Quintiles Pty Limited</s1><s2>Sydney</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Rovaris, Marco" sort="Rovaris, Marco" uniqKey="Rovaris M" first="Marco" last="Rovaris">Marco Rovaris</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neuroimaging Research Unit, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>2 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Comi, Giancarlo" sort="Comi, Giancarlo" uniqKey="Comi G" first="Giancarlo" last="Comi">Giancarlo Comi</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>MS Centre, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>15 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Filippi, Massimo" sort="Filippi, Massimo" uniqKey="Filippi M" first="Massimo" last="Filippi">Massimo Filippi</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neuroimaging Research Unit, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>2 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">03-0451872</idno><date when="2003">2003</date><idno type="stanalyst">PASCAL 03-0451872 INIST</idno><idno type="RBID">Pascal:03-0451872</idno><idno type="wicri:Area/PascalFrancis/Corpus">005187</idno><idno type="wicri:Area/PascalFrancis/Curation">000F39</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004D47</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004D47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a</title><author><name sortKey="Barkhof, Frederik" sort="Barkhof, Frederik" uniqKey="Barkhof F" first="Frederik" last="Barkhof">Frederik Barkhof</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MS-MRI Centre and Department of Radiology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Rocca, Mara" sort="Rocca, Mara" uniqKey="Rocca M" first="Mara" last="Rocca">Mara Rocca</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neuroimaging Research Unit, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>2 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Francis, Gordon" sort="Francis, Gordon" uniqKey="Francis G" first="Gordon" last="Francis">Gordon Francis</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Serono Laboratories</s1><s2>Rockland, MA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Serono Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Van Waesberghe, Jan Hein T M" sort="Van Waesberghe, Jan Hein T M" uniqKey="Van Waesberghe J" first="Jan-Hein T. M." last="Van Waesberghe">Jan-Hein T. M. Van Waesberghe</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MS-MRI Centre and Department of Radiology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Uitdehaag, Bernard M J" sort="Uitdehaag, Bernard M J" uniqKey="Uitdehaag B" first="Bernard M. J." last="Uitdehaag">Bernard M. J. Uitdehaag</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>MS-MRI Centre and Department of Neurology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Hommes, Otto R" sort="Hommes, Otto R" uniqKey="Hommes O" first="Otto R." last="Hommes">Otto R. Hommes</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>European Charcot Foundation</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Hartung, Hans Peter" sort="Hartung, Hans Peter" uniqKey="Hartung H" first="Hans-Peter" last="Hartung">Hans-Peter Hartung</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Karl-Franzens Universitat</s1><s2>Graz</s2><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Graz</wicri:noRegion></affiliation></author><author><name sortKey="Durelli, Luca" sort="Durelli, Luca" uniqKey="Durelli L" first="Luca" last="Durelli">Luca Durelli</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Neurology, University of Turin</s1><s2>Turin</s2><s3>ITA</s3><sZ>8 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Edan, Gilles" sort="Edan, Gilles" uniqKey="Edan G" first="Gilles" last="Edan">Gilles Edan</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Clinique Neurologique, Université de Rennes</s1><s2>Rennes</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Fernandez, Oscar" sort="Fernandez, Oscar" uniqKey="Fernandez O" first="Oscar" last="Fernandez">Oscar Fernandez</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Servicio de Neurología, Hospital Carlos Haya</s1><s2>Málaga</s2><s3>ESP</s3><sZ>10 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>Málaga</wicri:noRegion></affiliation></author><author><name sortKey="Seeldrayers, Pierette" sort="Seeldrayers, Pierette" uniqKey="Seeldrayers P" first="Pierette" last="Seeldrayers">Pierette Seeldrayers</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Neurology, C.H.U. de Charleroi, and Hôpital Erasme</s1><s2>Brussels</s2><s3>BEL</s3><sZ>11 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="S Rensen, Per" sort="S Rensen, Per" uniqKey="S Rensen P" first="Per" last="S Rensen">Per S Rensen</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Neurology, Rigshospitalet</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>12 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Margrie, Simon" sort="Margrie, Simon" uniqKey="Margrie S" first="Simon" last="Margrie">Simon Margrie</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Quintiles Pty Limited</s1><s2>Sydney</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Rovaris, Marco" sort="Rovaris, Marco" uniqKey="Rovaris M" first="Marco" last="Rovaris">Marco Rovaris</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neuroimaging Research Unit, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>2 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Comi, Giancarlo" sort="Comi, Giancarlo" uniqKey="Comi G" first="Giancarlo" last="Comi">Giancarlo Comi</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>MS Centre, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>15 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Filippi, Massimo" sort="Filippi, Massimo" uniqKey="Filippi M" first="Massimo" last="Filippi">Massimo Filippi</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neuroimaging Research Unit, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>2 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno><imprint><date when="2003">2003</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Beta interferon</term><term>Chemotherapy</term><term>Diagnosis</term><term>Human</term><term>Multiple sclerosis</term><term>Nuclear magnetic resonance imaging</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Sclérose en plaques</term><term>Interféron bêta</term><term>Imagerie RMN</term><term>Traitement</term><term>Chimiothérapie</term><term>Diagnostic</term><term>Homme</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the recently proposed diagnostic criteria for multiple sclerosis (MS) by McDonald, the modified magnetic resonance imaging (MRI) Barkhof criteria have been incorporated. We examined the validity of this implementation in the Early Treatment of MS study, a randomized, double-blind, placebo-controlled study of 22μg interferon β1a given subcutaneously once weekly in 309 patients with a first episode consistent with demyelinating disease (and abnormal MRI). Conversion to clinically definite MS (CDMS) within 2 years of follow-up, as evidenced by a new clinical episode, occurred in 41% of patients (independent of treatment) with gadolinium enhancement or nine or more T2 lesions versus 11% of those without either finding (p = 0.017); similarly, proportions converting were 44% versus 31% for infratentorial lesions (p = 0.026), 40% versus 35% for juxtacortical lesions (p = 0.413), and 41% versus 17% for three or more periventricular lesions (p = 0.034). The rate of conversion to CDMS based on the number of modified Barkhof criteria was 22% for two or fewer positive criteria, increasing to 47% with four positive criteria. For a cutoff of three positive criteria, the hazard ratio for time to CDMS was 2.3 (95% confidence interval, 1.17-4.55; p = 0.016). Treatment effect seemed more evident as the number of positive criteria increased, and the number of patients needed to avoid one patient converting to CDMS decreased from 50 in patients with one or two positive criteria to 5.6 in patients with four positive criteria. However, the study was not powered to detect statistically significant treatment by variable interaction, and this remains an important issue for further study.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0></fA01><fA02 i1="01"><s0>ANNED3</s0></fA02><fA03 i2="1"><s0>Ann. neurol.</s0></fA03><fA05><s2>53</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a</s1></fA08><fA11 i1="01" i2="1"><s1>BARKHOF (Frederik)</s1></fA11><fA11 i1="02" i2="1"><s1>ROCCA (Mara)</s1></fA11><fA11 i1="03" i2="1"><s1>FRANCIS (Gordon)</s1></fA11><fA11 i1="04" i2="1"><s1>VAN WAESBERGHE (Jan-Hein T. M.)</s1></fA11><fA11 i1="05" i2="1"><s1>UITDEHAAG (Bernard M. J.)</s1></fA11><fA11 i1="06" i2="1"><s1>HOMMES (Otto R.)</s1></fA11><fA11 i1="07" i2="1"><s1>HARTUNG (Hans-Peter)</s1></fA11><fA11 i1="08" i2="1"><s1>DURELLI (Luca)</s1></fA11><fA11 i1="09" i2="1"><s1>EDAN (Gilles)</s1></fA11><fA11 i1="10" i2="1"><s1>FERNANDEZ (Oscar)</s1></fA11><fA11 i1="11" i2="1"><s1>SEELDRAYERS (Pierette)</s1></fA11><fA11 i1="12" i2="1"><s1>SØRENSEN (Per)</s1></fA11><fA11 i1="13" i2="1"><s1>MARGRIE (Simon)</s1></fA11><fA11 i1="14" i2="1"><s1>ROVARIS (Marco)</s1></fA11><fA11 i1="15" i2="1"><s1>COMI (Giancarlo)</s1></fA11><fA11 i1="16" i2="1"><s1>FILIPPI (Massimo)</s1></fA11><fA14 i1="01"><s1>MS-MRI Centre and Department of Radiology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Neuroimaging Research Unit, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>2 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></fA14><fA14 i1="03"><s1>Serono Laboratories</s1><s2>Rockland, MA</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>MS-MRI Centre and Department of Neurology, VU Medical Centre</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>European Charcot Foundation</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Neurology, Karl-Franzens Universitat</s1><s2>Graz</s2><s3>AUT</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Neurology, University of Turin</s1><s2>Turin</s2><s3>ITA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>Clinique Neurologique, Université de Rennes</s1><s2>Rennes</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="09"><s1>Servicio de Neurología, Hospital Carlos Haya</s1><s2>Málaga</s2><s3>ESP</s3><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>Department of Neurology, C.H.U. de Charleroi, and Hôpital Erasme</s1><s2>Brussels</s2><s3>BEL</s3><sZ>11 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Neurology, Rigshospitalet</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>12 aut.</sZ></fA14><fA14 i1="12"><s1>Quintiles Pty Limited</s1><s2>Sydney</s2><s3>AUS</s3><sZ>13 aut.</sZ></fA14><fA14 i1="13"><s1>MS Centre, Department of Neuroscience, IRCCS San Raffaele</s1><s2>Milan</s2><s3>ITA</s3><sZ>15 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>Early Treatment of Multiple Sclerosis Study Group</s1><s3>INC</s3></fA17><fA20><s1>718-724</s1></fA20><fA21><s1>2003</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>16555</s2><s5>354000118306280050</s5></fA43><fA44><s0>0000</s0><s1>© 2003 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>10 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>03-0451872</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of neurology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>In the recently proposed diagnostic criteria for multiple sclerosis (MS) by McDonald, the modified magnetic resonance imaging (MRI) Barkhof criteria have been incorporated. We examined the validity of this implementation in the Early Treatment of MS study, a randomized, double-blind, placebo-controlled study of 22μg interferon β1a given subcutaneously once weekly in 309 patients with a first episode consistent with demyelinating disease (and abnormal MRI). Conversion to clinically definite MS (CDMS) within 2 years of follow-up, as evidenced by a new clinical episode, occurred in 41% of patients (independent of treatment) with gadolinium enhancement or nine or more T2 lesions versus 11% of those without either finding (p = 0.017); similarly, proportions converting were 44% versus 31% for infratentorial lesions (p = 0.026), 40% versus 35% for juxtacortical lesions (p = 0.413), and 41% versus 17% for three or more periventricular lesions (p = 0.034). The rate of conversion to CDMS based on the number of modified Barkhof criteria was 22% for two or fewer positive criteria, increasing to 47% with four positive criteria. For a cutoff of three positive criteria, the hazard ratio for time to CDMS was 2.3 (95% confidence interval, 1.17-4.55; p = 0.016). Treatment effect seemed more evident as the number of positive criteria increased, and the number of patients needed to avoid one patient converting to CDMS decreased from 50 in patients with one or two positive criteria to 5.6 in patients with four positive criteria. However, the study was not powered to detect statistically significant treatment by variable interaction, and this remains an important issue for further study.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17F</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Sclérose en plaques</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Multiple sclerosis</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Esclerosis en placa</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Interféron bêta</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Beta interferon</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Interferón beta</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Imagerie RMN</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Imaginería RMN</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0><s5>17</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0><s5>17</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0><s5>17</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>18</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>18</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>18</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Diagnostic</s0><s5>19</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Diagnosis</s0><s5>19</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Diagnóstico</s0><s5>19</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie inflammatoire</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Inflammatory disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad inflamatoria</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Cytokine</s0><s5>45</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cytokine</s0><s5>45</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Citoquina</s0><s5>45</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Imagerie médicale</s0><s5>53</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Medical imagery</s0><s5>53</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Imaginería médica</s0><s5>53</s5></fC07><fN21><s1>307</s1></fN21><fN82><s1>PSI</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Danemark</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Gueldre</li><li>Hollande-Septentrionale</li><li>Hovedstaden</li><li>Lombardie</li><li>Nouvelle-Galles du Sud</li><li>Piémont</li><li>Région Bretagne</li><li>Région de Bruxelles-Capitale</li></region><settlement><li>Amsterdam</li><li>Bruxelles</li><li>Copenhague</li><li>Milan</li><li>Nimègue</li><li>Rennes</li><li>Sydney</li><li>Turin</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Barkhof, Frederik" sort="Barkhof, Frederik" uniqKey="Barkhof F" first="Frederik" last="Barkhof">Frederik Barkhof</name></region><name sortKey="Hommes, Otto R" sort="Hommes, Otto R" uniqKey="Hommes O" first="Otto R." last="Hommes">Otto R. Hommes</name><name sortKey="Uitdehaag, Bernard M J" sort="Uitdehaag, Bernard M J" uniqKey="Uitdehaag B" first="Bernard M. J." last="Uitdehaag">Bernard M. J. Uitdehaag</name><name sortKey="Van Waesberghe, Jan Hein T M" sort="Van Waesberghe, Jan Hein T M" uniqKey="Van Waesberghe J" first="Jan-Hein T. M." last="Van Waesberghe">Jan-Hein T. M. Van Waesberghe</name></country><country name="Italie"><region name="Lombardie"><name sortKey="Rocca, Mara" sort="Rocca, Mara" uniqKey="Rocca M" first="Mara" last="Rocca">Mara Rocca</name></region><name sortKey="Comi, Giancarlo" sort="Comi, Giancarlo" uniqKey="Comi G" first="Giancarlo" last="Comi">Giancarlo Comi</name><name sortKey="Durelli, Luca" sort="Durelli, Luca" uniqKey="Durelli L" first="Luca" last="Durelli">Luca Durelli</name><name sortKey="Filippi, Massimo" sort="Filippi, Massimo" uniqKey="Filippi M" first="Massimo" last="Filippi">Massimo Filippi</name><name sortKey="Rovaris, Marco" sort="Rovaris, Marco" uniqKey="Rovaris M" first="Marco" last="Rovaris">Marco Rovaris</name></country><country name="États-Unis"><noRegion><name sortKey="Francis, Gordon" sort="Francis, Gordon" uniqKey="Francis G" first="Gordon" last="Francis">Gordon Francis</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Hartung, Hans Peter" sort="Hartung, Hans Peter" uniqKey="Hartung H" first="Hans-Peter" last="Hartung">Hans-Peter Hartung</name></noRegion></country><country name="France"><region name="Région Bretagne"><name sortKey="Edan, Gilles" sort="Edan, Gilles" uniqKey="Edan G" first="Gilles" last="Edan">Gilles Edan</name></region></country><country name="Espagne"><noRegion><name sortKey="Fernandez, Oscar" sort="Fernandez, Oscar" uniqKey="Fernandez O" first="Oscar" last="Fernandez">Oscar Fernandez</name></noRegion></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Seeldrayers, Pierette" sort="Seeldrayers, Pierette" uniqKey="Seeldrayers P" first="Pierette" last="Seeldrayers">Pierette Seeldrayers</name></region></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="S Rensen, Per" sort="S Rensen, Per" uniqKey="S Rensen P" first="Per" last="S Rensen">Per S Rensen</name></region></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Margrie, Simon" sort="Margrie, Simon" uniqKey="Margrie S" first="Simon" last="Margrie">Simon Margrie</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 004D47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:03-0451872
|texte= Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a
}}
| This area was generated with Dilib version V0.6.33. |  |